Company TRACON Pharmaceuticals, Inc.

Equities

TCON

US89237H2094

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.4298 USD +4.80% Intraday chart for TRACON Pharmaceuticals, Inc. +15.54% +145.46%

Business Summary

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize products in the United States. The Company’s clinical-stage oncology product candidate is TRC102, which is a small molecule that has been studied in Phase 1 and Phase 2 trials for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors and YH001, which is a monospecific investigational cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody. TRC102 is a small molecule in clinical development to reverse resistance to specific chemotherapeutics by inhibiting DNA base excision repair (BER). Its clinical-stage product candidate, Envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma.

Number of employees: 17

Sales per Business

USD in Million2022Weight2023Weight Delta
Therapeutics
100.0 %
0 nan % 12 100.0 % -

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 nan % 12 100.0 % -

Managers

Managers TitleAgeSince
Chief Executive Officer 60 06-06-30
Director of Finance/CFO 43 15-07-31
Chief Tech/Sci/R&D Officer 69 20-04-30
General Counsel - 21-07-19

Members of the board

Members of the board TitleAgeSince
Director/Board Member 66 14-12-25
Director/Board Member 54 20-03-18
Director/Board Member 66 15-02-24
Director/Board Member 71 08-08-31
Director/Board Member 73 14-06-30
Chief Executive Officer 60 06-06-30
Director/Board Member 64 21-10-11
Director/Board Member 60 21-03-01

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 45,504,501 43,230,434 ( 95.00 %) 0 95.00 %

Shareholders

NameEquities%Valuation
Ikarian Capital LLC
8.880 %
2,765,530 8.880 % 500 561 $
Lincoln Park Capital LLC
7.495 %
2,334,423 7.495 % 422 531 $
716,925 2.302 % 129 763 $
Acadian Asset Management LLC
1.329 %
413,909 1.329 % 74 918 $
Squarepoint OPS LLC
1.324 %
412,271 1.324 % 74 621 $
406,417 1.305 % 73 561 $
Vanguard Group, Inc. (Subfiler)
0.8437 %
262,772 0.8437 % 47 562 $
BlackRock Institutional Trust Co. NA
0.8389 %
261,262 0.8389 % 47 288 $
Boothbay Fund Management LLC
0.8311 %
258,844 0.8311 % 46 851 $
Geode Capital Management LLC
0.6704 %
208,786 0.6704 % 37 790 $

Company contact information

TRACON Pharmaceuticals, Inc.

4350 La Jolla Village Drive Suite 800

92122-1243, San Diego

+

http://www.traconpharma.com
address TRACON Pharmaceuticals, Inc.(TCON)